SLS — SELLAS Life Sciences Group, Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1390478 ·
Last close
$10.01
Market Cap
$1.97B
52W High
$15.88
52W Low
$4.83
ADV30
10,138,075
Next earnings
2026-08-11
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -9,252,000 | -8,407,000 | 114,177,000 | 107,097,000 | 6,765,000 |
| Dec 2025 | 0 | — | -8,255,000 | -7,658,000 | 78,345,000 | 71,793,000 | 7,474,000 |
| Sep 2025 | 0 | — | -7,083,000 | -6,791,000 | 51,555,000 | 44,320,000 | 5,925,000 |
| Jun 2025 | 0 | — | -6,873,000 | -6,601,000 | 32,305,000 | 25,297,000 | 6,156,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-28,165,000
Investing CF
$0
Financing CF
$106,865,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-0.25
As of
2026-06-07
Balance + Analyst (yfinance extras)
Retained Earnings
$-283,395,000
Inventory
—
Receivables
—
ST Investments
—
EBIT TTM
$-31,463,000
Pretax Income TTM
$-29,457,000
Interest Exp TTM
—
Analysts
2
Annual Trend (SEC EDGAR, last 5y)
Revenues vs Net Income (last 5y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -28,274,000 | -26,863,000 | 78,345,000 | 7,474,000 | — | -28,389,000 |
| Dec 2024 | 0 | -31,513,000 | -30,881,000 | 19,432,000 | 9,967,000 | — | -35,402,000 |
| Dec 2023 | 0 | -37,869,000 | -37,340,000 | 6,219,000 | 14,195,000 | — | -31,410,000 |
| Dec 2022 | 1,000,000 | -31,950,000 | -41,301,000 | 20,943,000 | 16,092,000 | — | -23,809,000 |
| Dec 2021 | — | — | — | — | — | — | — |
TTM Snapshot
Revenues TTM
$16,690,000
NetIncome TTM
$-30,482,000
OpCashFlow TTM
$0
Assets (Latest)
$19,432,000
Forward EPS
$-0.12
Max Pain — expiry 2026-08-07
max pain strike: $11.50 · spot: $10.01 · call oi: 17,429 · put oi: 3,592
Expected Move to 2026-08-07:
±$2.00
(19.98%) —
implied range
$8.01 –
$12.01
· ATM straddle on $10.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| RAPP | Rapport Therapeutics, Inc. | $1.96B | $40.98 | — |
| ZBIO | Zenas BioPharma, Inc. | $1.98B | $31.44 | — |
| NBTX | Nanobiotix S.A. | $1.95B | $38.38 | — |
| PVLA | PALVELLA THERAPEUTICS, INC. | $1.99B | $139.04 | — |
| HCM | HUTCHMED (China) Ltd | $1.93B | $11.13 | — |
News headlines (Yahoo Finance, 1h cache)
SLS Stock In Spotlight After Vanguard Capital Discloses 5.19% Stake – Retail Calls It ‘Huge Vote Of Conviction’ As AML Trial Readout Nears
2026-07-31 16:32 · Yahoo
SLS Stock Turns Green After 3-Day Rout: Five Investors Add Shares As Key AML Trial Nears Final Trigger
2026-07-30 06:53 · Yahoo
SLS Stock Heads For Worst Month In Over 2 Years — But Retail Bulls ‘Hold’ For AML Readout And Buyout Hopes
2026-07-29 03:33 · Yahoo
SLS Stock Hits 1-Month Low On China Arbitration Blow — Retail Bulls Call It A ‘Nothingburger’ Ahead Of AML Readout
2026-07-28 05:06 · Yahoo
SLS Stock Climbs Premarket: Here’s What Smart Money Is Doing As Sellas Nears Critical Phase 3 AML Readout
2026-07-27 08:17 · Yahoo
Sellas CEO Angelos Stergiou Says ‘100% Certain’ AI Can Be Used To Beat Cancer
2026-07-24 13:44 · Yahoo
SLS Stock Rises Overnight: Retail Traders Call New AML Survival Data 'Huge' Ahead Of CEO’s Fox Appearance
2026-07-24 05:11 · Yahoo
SLS Stock July Rout Deepens: ‘Pharma Bro’ Martin Shkreli Questions Timing Of AML Trial, Says Data May Wait Until Christmas
2026-07-23 06:27 · Yahoo
SLS Stock Tracks Worst Month Since March: Investor Slashes Stake By Over 30% As Quiet Period Begins Ahead Of AML Readout
2026-07-22 02:18 · Yahoo
SLS Stock Rises Overnight: Retail Thinks CEO Just Dropped Buyout Clues Ahead Of Fox Appearance
2026-07-21 04:08 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.